Bernstein analyst Rebecca Liang maintained a Hold rating on BeiGene (ONC – Research Report) today and set a price target of $259.00. The ...
Bernstein raised the firm’s price target on BeiGene (ONC) to $259 from $207 and keeps a Market Perform rating on the shares. The firm sees more ...
Beijing-based pharma, BeiGene’s Brukinsa (zanubrutinib) has been approved by the US Food and Drug Administration (FDA) for chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL).
After hours: March 7 at 7:54:21 PM EST Loading Chart for ONC ...